公开(公告)号：WO2005093048A1

公开(公告)日：2005-10-06

申请号：PCT/CA2005/000456

申请日：2005-03-29

Applicant: ARIUS RESEARCH, INC.

Inventor： YOUNG, David, S., F. ,  HAHN, Susan, E. ,  FINDLAY, Helen, P. ,  MCCONKEY, Fortunata ,  KELLEHER, Michelle ,  WARNER, Andrea

IPC: C12N5/12

CPC classification number: C07K16/303 ,  A61K47/6851 ,  C07K16/30 ,  C07K16/3069 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57438 ,  G01N33/57449 ,  G01N33/57476 ,  G01N33/6893

Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells. The invention further relates to such diagnosis and treatment which revolves around the ability of the 5LAC­23 monoclonal antibody (or antigenic binding fragments derived therefrom) to bind with the Laminin Receptor 1 Precursor Protein 37LRP; and most particularly to diagnosis and treatment of Hepatocellular Carcinoma by various means which rely upon direct binding of 5LAC-23 with the particular antigenic moiety specifically recognized thereby and generally overexpressed in Hepatocellular carcinoma cells.

Abstract translation: 本发明涉及使用新的筛选范例来生产患者癌症疾病修饰抗体的方法。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。 本发明还涉及这样的诊断和治疗，其围绕5LAC23单克隆抗体（或其衍生的抗原结合片段）与层粘连蛋白受体1前体蛋白37LRP结合的能力; 最特别的是通过各种手段诊断和治疗肝细胞癌，这些方法依赖于5LAC-23与由此特异性识别的特定抗原部分的直接结合，并且通常在肝细胞癌细胞中过表达。

公开(公告)号：WO2007098575A1

公开(公告)日：2007-09-07

申请号：PCT/CA2007/000281

申请日：2007-02-23

Applicant: ARIUS RESEARCH, INC.

Inventor： YOUNG, David, S., F. ,  FINDLAY, Helen, P. ,  HAHN, Susan, E. ,  CECHETTO, Lisa, M. ,  MCCONKEY, Fortunata

IPC: C07K16/30 ,  A61K38/00 ,  A61K39/395 ,  A61K47/48 ,  A61K51/08 ,  A61P35/00 ,  A61P37/04 ,  C07K16/28 ,  C12P21/08 ,  G01N33/574 ,  G01N33/577 ,  C07K14/705

CPC classification number: C07K16/2884 ,  A61K47/6849 ,  A61K47/6897 ,  A61K49/0013 ,  A61K49/0058 ,  A61K2039/505 ,  B82Y5/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/73 ,  G01N33/5082 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/70585

Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumour cells evidencing surface expression of CD44; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

Abstract translation: 本发明涉及癌症疾病的诊断和治疗，特别涉及证明CD44表面表达的肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。

公开(公告)号：WO2007095745A1

公开(公告)日：2007-08-30

申请号：PCT/CA2007/000278

申请日：2007-02-22

Applicant: ARIUS RESEARCH, INC.

Inventor： YOUNG, David, S., F. ,  FINDLAY, Helen, P. ,  HAHN, Susan, E. ,  CECHETTO, Lisa, M. ,  MCCONKEY, Fortunata ,  SAYEGH, Daad

IPC: C12N5/16 ,  A61K31/00 ,  A61K38/19 ,  A61K39/395 ,  A61K47/48 ,  A61K51/10 ,  C07K16/30 ,  C12P21/08 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K16/30 ,  A61K38/21 ,  A61K47/6851 ,  A61K51/1045 ,  A61K2039/505

Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Abstract translation: 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。